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VALUE IN HEALTH - MAY 2020 S361$40 years diagnosed with COPD who newly initiated roflumilast fromMarch 2011 to
September 2015, were identified from the Truven MarketScan database. We
measured demographic and clinical characteristics in the 12-month period prior to
first date of use, the index date. Adherence was measured using prescription days
covered (PDC) $ 80% threshold over a 6-month period. We calculated persistence as
the proportion of patients that did not discontinue roflumilast, defined as a gap of
.30 days. Results: A total of 9919 patients were includedwith amean age of 67.7 years
(610.1) and 4972 (50.1%) were female. Inhaled corticosteroids (ICS) and long-acting beta
agonists (LABA), single inhaler use or in combination, were frequently used, 7300 (73.6%)
and 7073 (71.3%) respectively, in the baseline period. We also captured multiple COPD
medication use prior to the index date. Accordingly, LABA and ICS 6903 (69.6%) were
commonly prescribed followed by long acting muscarinic antagonists (LAMA) and ICS
(5112, 51.5%). The overall PDC over a 6-month period was 69% with only 3104 (48.8%)
patients being adherent (PDC$ 80%). Over the same 6-month period, only 2581 (26.0%)
were persistent. We also measured PDC over 3-month (81%) and 12-month (56%). In
addition, persistence to roflumilast was 4899 (49.4%) and 1196 (12.1%) over a 3- and 12-
month period respectively. Conclusions: A substantial number of adult patients with
COPD have sub-optimal adherence and persistence to roflumilast. Reasons for low
adherence or discontinuation such as prevalence of treatment-related adverse effects
deserve further investigation.
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Objectives: Provide evidence to support the Asthma Daytime Symptom Diary (ADSD)
and the Asthma Nighttime Symptom Diary (ANSD) to measure change in asthma
symptom severity in clinical trials. Methods: The study was used to assess item per-
formance, factor structure, reliability, construct validity, and sensitivity to change. ADSD
was completed each evening; ANSD was completed seven consecutive days at begin-
ning, middle and end of trial. Meaningful change estimates were derived using anchor-
and distribution-based approaches. Results: ADSD (n=428) and ANSD (n=309) study
populationsweremeanages52.1and51.4years;predominantly female (n=321,66.6%and
n=201, 65.05%); and white (n=405, 84.02% and n=247, 79.94%). Both six-item measures
showed high internal consistency (Cronbach’s alpha coefficients = 0.95 and 0.96); ADSD
score reproducibilitywas observed among subjects stable onPGI-S between baseline and
week 26 (ICC = 0.89). Similar ANSD datawere insufficient to present ICC. Factor analyses
produced high factor loadings (.0.78) for all constituent items supporting overall latent
traits of daytime and nighttime symptom severity. As hypothesized, correlations
(Spearman’s) ofgreatermagnitudewereobservedwithdisease-proximalmeasures,ACQ-
5 and AQLQ symptoms (0.50 and -0.47 and 0.48 and -0.49), than distal measures, AQLQ
activity limitations and EQ-5D-5L VAS (-0.39 and -0.36 and -0.43 and -0.39). ADSD and
ANSD scoreswere significantly lower (all p,0.0001) among subgroups categorized onan
external anchor as healthier (lower PGIS-PM global symptom severity, better ACQ-5
asthma control, andhigherHRQOLbased onEQ-5D-5LVAS). Triangulationof anchor- and
distribution-based methods supports a 2-point threshold for interpreting meaningful
change forADSDandANSD. Conclusions: Evidence supporting psychometric properties
and meaningful change scores are presented for ANSD and ADSD, although additional
data to confirm ANSD reliability are warranted.
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Objectives: The aim of this study was to assess the barriers to and competency with
the use of Metered Dose Inhaler (MDI) and its impact on disease control among adult
asthmatic patients. Methods: A prospective cross-sectional study was conducted in
University of Gondar comprehensive specialized hospital outpatient department (OPD)
chronic followupfrom12-March-2018to15-May-2018.Patientswere interviewedface to
face with questions which determined their competency, asthma control level and bar-
riers for inhaler use. Results: Overall, 307 asthmatic patients were included in the study.
More than half of participants were females, 170 (55.4%) and lived in urban area 185
(60.3%). Themean age of the respondentswas 51.77with a standard deviation of615.40.
The cost ofmedication, 282 (91.9%) and the perception thatmedication should beused in
response to symptoms but not on a regular basis 277 (90.2%) were the most identified
barriers. Only 56 (18.2%) were competent for Metered Dose Inhaler use (MDIU) and 17
(5.5%) patients had well controlled asthma. Being not competent AOR 0.168[0.41-0.687]
wasoneof the factorsdecreasingasthmacontrol.Conclusions: Generally from this study,
cost of the medication and the perception that medication should be used only for
symptoms were the major identified barriers that affect the MDI use among asthmatic
patients. Patients show very poor competence to their MDI which in turn led to poor
asthma control. So, patients need to be taught the correct inhaler technique in the
hospital and pharmacy while they came for follow up every time.Respiratory-Related Disorders - Real World Data &
Information Systems
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Objectives: Patients with Severe Eosinophilic Asthma (SEA) represent only 5-10% of
the population with asthma but their healthcare resource use (HRU) represents the
largest proportion of asthma expenditures. Understanding the patterns of HRU after
initiation of mepolizumab, in real-life settings, is very relevant to inform healthcare
systems resource allocation. Methods: REALITI-A, a multicenter, international, pro-
spective study, enrolled patients with SEA, who initiated mepolizumab. These pre-
liminary analyses include subjects from 51 centers in 7 countries. 12-month of
relevant historical data was required before enrolment for all participants to allow
for a standardized period of history to describe participant’s demographics, disease
burden and previous medication use. Specific HRU was compared with a 12-month
prospective observation period for each patient. Changes in annual rates from
baseline in each health resource category were evaluated. Changes in medication use
is reported elsewhere. Results: Preliminary data were available for 368 treated
subjects who completed 12 months of follow-up. 19% of subjects discontinued
mepolizumab within 1-year. Annualized rates of asthma-related hospitalizations,
emergency room visits, planned and unplanned office or clinic visits, and home visits
were reduced after the initiation of mepolizumab. On average, rates of asthma-
related hospitalizations were reduced by 55.8% (0.52, 95% CI [0.41, 0.67] vs. 0.23, 95%
CI [0.16, 0.33]) emergency visits by 55.7% (0.61 [0.45, 0.81] vs. 0.27 [0.20, 0.36]);
planned and unplanned office visits by 52.2% (4.92 [4.46, 5.44] vs. 2.35, [1.97, 2.79] ).
The annual rate on the use of telephone calls to providers (0.90, [0.71, 1.14] vs. 1.13,
[0.54, 2.34]) or home visits (0.12, [0.06, 0.25] vs 0.10, [0.02, 0.44]) was similar before
and after mepolizumab. Conclusions: The use of mepolizumab in patients with se-
vere eosinophilic asthma, in real-world settings, resulted in substantial reductions in
healthcare resource use, particularly hospitalizations, emergency and office visits.
Funding: GSK (204710)
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Objectives: Severe asthma, although infrequent, generates an important clinical and
economic burden in both patients and healthcare system. We aimed to describe
demographic and clinical characteristics, exacerbations, healthcare resource utiliza-
tion (HRU), and annual direct medical costs in a severe asthma patient cohort in
Colombia.Methods: Costof illness study frompayerperspective. Patientswithclinician-
confirmedsevere asthmadiagnosis (GINAcriteria) fromtwospecialized referencecenters
between January 2014 and August 2018 were included. The last year within this period
under GINA step 4/5 therapy was observed for each patient. Clinical information was
extracted from medical records, and HRU from hospital invoices and public price lists.
Results: 147 patients were included, 59% female. Mean (6SD) age and timewith asthma
diagnosis was 46615 and 21617 years, respectively. Most frequent comorbidities were
allergic rhinitis (70%), conjunctivitis (27%) and hypertension (19%). Most common sensi-
tization cause was house dust mite (61%). Median baseline blood eosinophil count was
260 cells/ml (range 10-4,040),mean total IgE serum levelwas 69761,893 IU/ml. Themean
annual frequency of HRU was 5.064.0 for laboratory tests, 4.161.2 for medical visits,
1.061.5 for emergency visits, 0.360.7 for hospitalizations, and 0.160.3 for ICU. Omali-
zumabwas prescribed in 42.2% of patients, with a mean among users of 30.2620.3 vials
per year. Mean annual direct cost for outpatient care was 4,743.666,331.1 USD (range
256.7-31,286.1) (1USD=2,956.4 COP);medicationswere responsible for98%of costs. Data
from 55 hospitalizations was obtained, 4 in ICU. Mean stay and cost per episode were
6.564.9 days and 1,010.561,379.9 USD in general ward, and 14.164.1 days and
3768.963748.2 USD in ICU. Conclusions: Severe asthma is a costly disease for the
Colombian health system. Most of the direct outpatient medical costs in this cohort
were caused by pharmacological therapy, particularly omalizumab. Funding: GSK
(PRJ2813).
